FDA Approved: ENBREL — Supplemental Application (Immunex Corporation)

View source ↗

Summary

FDA approved a supplemental application for ENBREL (etanercept), expanding its label with additional indications. The submission status indicates approval (AP).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Juvenile Idiopathic Arthritis
• Plaque Psoriasis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• ENBREL (etanercept)

Snippet

SUPPL AP for ENBREL (ETANERCEPT)